TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® ...

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair ...

The approval in adolescent patients was based on evidence from the phase 3 SINUS-24 and SINUS-52 trials. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab is the first treatment in the U.S. for CRSwNP for adolescents. The approval is supported by data from ...

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic ...

Please provide your email address to receive an email when new articles are posted on . EVEREST represents the first head-to-head study of these biologics for CRSwNP. Differences between the biologics ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...